KR102036393B1 - 아미딘 치환된 베타 - 락탐 화합물, 그의 제조법 및 항박테리아제로서의 용도 - Google Patents

아미딘 치환된 베타 - 락탐 화합물, 그의 제조법 및 항박테리아제로서의 용도 Download PDF

Info

Publication number
KR102036393B1
KR102036393B1 KR1020147020410A KR20147020410A KR102036393B1 KR 102036393 B1 KR102036393 B1 KR 102036393B1 KR 1020147020410 A KR1020147020410 A KR 1020147020410A KR 20147020410 A KR20147020410 A KR 20147020410A KR 102036393 B1 KR102036393 B1 KR 102036393B1
Authority
KR
South Korea
Prior art keywords
amino
thiazol
imino
ethoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147020410A
Other languages
English (en)
Korean (ko)
Other versions
KR20140114390A (ko
Inventor
부르크하르트 클렌케
이리트 비간트
귀도 쉬퍼
하이케 브뢰츠-외스테르헬트
사마렌드라 엔. 마이티
제항기르 칸
안드헤 레디
지시앙 양
모스타파 헤나
구오펭 지아
오 리공
홍 리앙
주디 입
추안준 가오
사비하 타자뮬
라힘 모하마드
강굴리 비스와지트
Original Assignee
아이쿠리스 게엠베하 운트 코. 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이쿠리스 게엠베하 운트 코. 카게 filed Critical 아이쿠리스 게엠베하 운트 코. 카게
Publication of KR20140114390A publication Critical patent/KR20140114390A/ko
Application granted granted Critical
Publication of KR102036393B1 publication Critical patent/KR102036393B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147020410A 2012-01-24 2013-01-23 아미딘 치환된 베타 - 락탐 화합물, 그의 제조법 및 항박테리아제로서의 용도 Expired - Fee Related KR102036393B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
EP12152279.1 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Publications (2)

Publication Number Publication Date
KR20140114390A KR20140114390A (ko) 2014-09-26
KR102036393B1 true KR102036393B1 (ko) 2019-10-24

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147020410A Expired - Fee Related KR102036393B1 (ko) 2012-01-24 2013-01-23 아미딘 치환된 베타 - 락탐 화합물, 그의 제조법 및 항박테리아제로서의 용도

Country Status (42)

Country Link
US (2) US9556165B2 (https=)
EP (1) EP2806873B1 (https=)
JP (1) JP5869701B2 (https=)
KR (1) KR102036393B1 (https=)
CN (1) CN104203237A (https=)
AP (1) AP2014007880A0 (https=)
AR (1) AR089796A1 (https=)
AU (1) AU2013211575B2 (https=)
BR (1) BR112014017968A8 (https=)
CA (1) CA2862338C (https=)
CL (1) CL2014001956A1 (https=)
CO (1) CO7101240A2 (https=)
CU (1) CU24273B1 (https=)
CY (1) CY1117955T1 (https=)
DK (1) DK2806873T3 (https=)
EA (1) EA027126B1 (https=)
EC (1) ECSP14010249A (https=)
ES (1) ES2592403T3 (https=)
HR (1) HRP20161171T1 (https=)
HU (1) HUE030452T2 (https=)
IL (1) IL233805A (https=)
IN (1) IN2014MN01640A (https=)
LT (1) LT2806873T (https=)
MA (1) MA35905B1 (https=)
ME (1) ME02532B (https=)
MX (1) MX346602B (https=)
MY (1) MY173843A (https=)
NZ (1) NZ626951A (https=)
PE (1) PE20142345A1 (https=)
PH (1) PH12014501671B1 (https=)
PL (1) PL2806873T3 (https=)
PT (1) PT2806873T (https=)
RS (1) RS55210B1 (https=)
SG (1) SG11201403930XA (https=)
SI (1) SI2806873T1 (https=)
SM (1) SMT201600354B (https=)
TN (1) TN2014000297A1 (https=)
TW (1) TWI659953B (https=)
UA (1) UA110880C2 (https=)
UY (1) UY34585A (https=)
WO (1) WO2013110643A1 (https=)
ZA (1) ZA201405057B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103583A1 (en) * 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
MX373444B (es) 2014-03-24 2020-04-30 Novartis Ag Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas.
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
PL3353175T3 (pl) * 2015-09-23 2021-02-22 Novartis Ag Sole i postacie stałe antybiotyku monobaktamowego
US20180339983A1 (en) 2015-12-15 2018-11-29 Merck Sharp & Dohme Corp. Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
CA3016341A1 (en) * 2016-03-07 2017-09-14 Merck Sharp & Dohme Corp. Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
IL264686B2 (en) 2016-08-26 2024-07-01 Codexis Inc Engineered imine reductases and methods for reversible amination of ketone and amine compounds
CA3043976A1 (en) 2016-11-18 2018-05-24 Aicuris Gmbh & Co. Kg Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
AU2017339587A1 (en) 2016-12-21 2019-07-04 Aicuris Gmbh & Co. Kg Combination therapy with amidine substituted ß-lactam compounds and ß-lactamase inhibitors for infections with antibiotic resistant bacterial strains
CN111132973A (zh) 2017-07-18 2020-05-08 拜耳作物科学股份公司 取代的3-杂芳氧基-1h-吡唑及其盐及其作为除草活性物质的用途
TW201920163A (zh) 2017-07-28 2019-06-01 德商艾庫里斯抗感染治療有限公司 (2s)‐2‐[[(z)‐[1‐(2‐胺基‐4‐噻唑基)‐2‐[[(3s)‐2,2‐二甲基‐4‐側氧基‐1‐(磺氧)‐3‐吖丁啶基]胺基]‐2‐氧亞乙基]胺基]氧基]‐3‐[4‐[亞胺基[(3r)‐3-哌啶基胺基]甲基]苯氧基]-丙酸之晶型
JP7235718B2 (ja) 2017-08-02 2023-03-08 ノバルティス アーゲー モノバクタム系抗生物質およびその中間体を製造するための化学的方法
KR102455390B1 (ko) * 2017-10-02 2022-10-17 아릭사 파마슈티컬스 인코포레이티드 아즈트레오남 유도체 및 이의 용도
EP3691639B1 (en) * 2017-10-02 2023-11-15 Merck Sharp & Dohme LLC Chromane monobactam compounds for the treatment of bacterial infections
WO2019144969A1 (zh) 2018-01-29 2019-08-01 南京明德新药研发股份有限公司 用于治疗细菌感染的单环β-内酰胺化合物
KR20210083285A (ko) * 2018-11-13 2021-07-06 난징 산홈 팔마세우티칼 컴퍼니 리미티드 모노박탐 화합물 및 그의 사용
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN114828850B (zh) 2019-12-19 2024-08-13 深圳嘉科生物科技有限公司 化合物在制药中的应用
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺化合物及其制备方法和应用
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
WO2022011626A1 (en) * 2020-07-16 2022-01-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
US12516048B2 (en) 2020-08-06 2026-01-06 Ningxia Academy Of Agriculture And Forestry Sciences B-lactam compounds, their preparation and use as antibacterial agents
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
AU2021473165B2 (en) * 2021-11-09 2025-05-22 Guangzhou HC New Drug Research Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF
GEAP202416514A (en) 2021-11-18 2024-08-26 Merck Sharp & Dohme Llc Chromane amidine monobactam antibiotics
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
CN118255695B (zh) * 2024-02-26 2025-03-14 广州艾奇西医药科技有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010324A1 (en) 1997-08-29 1999-03-04 Naeja Pharmaceutical Inc. AZETIDINONE DERIVATIVES AS β-LACTAMASE INHIBITORS
WO2002022613A1 (en) 2000-09-14 2002-03-21 Pantherix Limited 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
WO2008116813A2 (en) 2007-03-23 2008-10-02 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
EP0336667A3 (en) 1988-04-04 1991-04-10 E.R. Squibb & Sons, Inc. [3S(Z)]-3-[[(2-amino-4-thiazolyl)[[2-(hydroxyamino)-2-oxoethoxy]imino]acetyl]-amino]-2,2-dimethyl-4-oxo-1-azetidinyl sulfate
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US7622502B2 (en) 2004-01-27 2009-11-24 Merck Frosst Canada & Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
ATE532514T1 (de) 2005-09-23 2011-11-15 Ms Science Corp Piperidin- und piperazinderivate
CA2783572C (en) 2005-12-07 2016-08-09 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
NZ570495A (en) 2006-02-14 2011-10-28 Ihara Chemical Ind Co Process for production of 5-alkoxy-4-hydroxymethylpyrazole compound
EP1994035A1 (en) 2006-03-16 2008-11-26 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
JP2012512863A (ja) * 2008-12-19 2012-06-07 ファイザー・インク モノカルバム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010324A1 (en) 1997-08-29 1999-03-04 Naeja Pharmaceutical Inc. AZETIDINONE DERIVATIVES AS β-LACTAMASE INHIBITORS
WO2002022613A1 (en) 2000-09-14 2002-03-21 Pantherix Limited 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
WO2008116813A2 (en) 2007-03-23 2008-10-02 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections

Also Published As

Publication number Publication date
CA2862338A1 (en) 2013-08-01
WO2013110643A1 (en) 2013-08-01
ECSP14010249A (es) 2015-12-31
ME02532B (me) 2017-02-20
CU20140090A7 (es) 2014-12-26
EA201400838A1 (ru) 2014-12-30
EP2806873B1 (en) 2016-06-15
IN2014MN01640A (https=) 2015-05-22
MX346602B (es) 2017-03-24
CN104203237A (zh) 2014-12-10
AU2013211575A1 (en) 2014-07-24
CL2014001956A1 (es) 2014-11-07
IL233805A0 (en) 2014-09-30
BR112014017968A2 (https=) 2017-06-20
AU2013211575B2 (en) 2017-03-02
PH12014501671A1 (en) 2014-11-10
ES2592403T3 (es) 2016-11-30
IL233805A (en) 2016-06-30
JP5869701B2 (ja) 2016-02-24
UY34585A (es) 2013-09-02
PL2806873T3 (pl) 2016-12-30
US9782390B2 (en) 2017-10-10
UA110880C2 (uk) 2016-02-25
CO7101240A2 (es) 2014-10-31
NZ626951A (en) 2016-03-31
HK1203389A1 (zh) 2015-10-30
LT2806873T (lt) 2016-10-10
PH12014501671B1 (en) 2020-02-28
EA027126B1 (ru) 2017-06-30
CA2862338C (en) 2019-04-16
KR20140114390A (ko) 2014-09-26
MA35905B1 (fr) 2014-12-01
ZA201405057B (en) 2017-09-27
BR112014017968A8 (pt) 2017-07-11
JP2015504907A (ja) 2015-02-16
US20150045340A1 (en) 2015-02-12
HRP20161171T1 (hr) 2016-11-04
HUE030452T2 (en) 2017-05-29
US20170100379A1 (en) 2017-04-13
MX2014008915A (es) 2014-08-26
PE20142345A1 (es) 2015-01-09
AR089796A1 (es) 2014-09-17
SMT201600354B (it) 2016-11-10
SG11201403930XA (en) 2014-08-28
CU24273B1 (es) 2017-08-08
CY1117955T1 (el) 2017-05-17
RS55210B1 (sr) 2017-01-31
TN2014000297A1 (en) 2015-12-21
TW201343643A (zh) 2013-11-01
EP2806873A1 (en) 2014-12-03
AP2014007880A0 (en) 2014-08-31
SI2806873T1 (sl) 2016-10-28
DK2806873T3 (en) 2016-08-29
TWI659953B (zh) 2019-05-21
PT2806873T (pt) 2016-09-23
MY173843A (en) 2020-02-24
US9556165B2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
KR102036393B1 (ko) 아미딘 치환된 베타 - 락탐 화합물, 그의 제조법 및 항박테리아제로서의 용도
CA2783572C (en) Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
US8252782B2 (en) Monocarbams
US12516048B2 (en) B-lactam compounds, their preparation and use as antibacterial agents
HU194876B (en) Process for production of new derivatives of 1-sulpha-2-azetidinon and medical preparatives containing these compounds
KR20160108400A (ko) 7-옥소-1,6-디아자바이사이클로[3.2.1]옥탄 유도체 및 이의 항박테리아제로서의 용도
CN108602822A (zh) 含有7-氧代-6-(硫氧基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的化合物及其在治疗细菌感染中的用途
EP4165039B1 (en) Novel monobactam compounds, their preparation and use as antibacterial agents
HK1203389B (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
OA17341A (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents.
SK4122002A3 (en) 7-Acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof
JPH07304779A (ja) セフェム化合物、その製造方法及び該化合物を含む抗菌剤
WO2001057041A1 (en) 1-methylcarbapenem compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221019

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221019